WillowV1, Main, Exploration, bibRecord, 000666

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.

Identifieur interne : 000666 ( Main/Exploration ); précédent : 000665; suivant : 000667

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.

Auteurs : Anthony R. Mato ; Meghan Thompson [États-Unis] ; John N. Allan [États-Unis] ; Danielle M. Brander [États-Unis] ; John M. Pagel [États-Unis] ; Chaitra S. Ujjani [États-Unis] ; Brian T. Hill [États-Unis] ; Nicole Lamanna [États-Unis] ; Frederick Lansigan [États-Unis] ; Ryan Jacobs [États-Unis] ; Mazyar Shadman [États-Unis] ; Alan P. Skarbnik [États-Unis] ; Jeffrey J. Pu [États-Unis] ; Paul M. Barr [États-Unis] ; Alison R. Sehgal [États-Unis] ; Bruce D. Cheson [États-Unis] ; Clive S. Zent [États-Unis] ; Hande H. Tuncer [États-Unis] ; Stephen J. Schuster [États-Unis] ; Peter V. Pickens [États-Unis] ; Nirav N. Shah [États-Unis] ; Andre Goy [États-Unis] ; Allison M. Winter [États-Unis] ; Christine Garcia [États-Unis] ; Kaitlin Kennard [États-Unis] ; Krista Isaac [États-Unis] ; Colleen Dorsey [États-Unis] ; Lisa M. Gashonia [États-Unis] ; Arun K. Singavi [États-Unis] ; Lindsey E. Roeker [États-Unis] ; Andrew Zelenetz [États-Unis] ; Annalynn Williams [États-Unis] ; Christina Howlett [États-Unis] ; Hanna Weissbrot [États-Unis] ; Naveed Ali [États-Unis] ; Sirin Khajavian [États-Unis] ; Andrea Sitlinger [États-Unis] ; Eve Tranchito [États-Unis] ; Joanna Rhodes [États-Unis] ; Joshua Felsenfeld [États-Unis] ; Neil Bailey [États-Unis] ; Bhavisha Patel [États-Unis] ; Timothy F. Burns [États-Unis] ; Melissa Yacur [États-Unis] ; Mansi Malhotra [États-Unis] ; Jakub Svoboda [États-Unis] ; Richard R. Furman [États-Unis] ; Chadi Nabhan [États-Unis]

Source :

Haematologica [ 1592-8721 ] ; 2018.

RBID : pubmed:29880613

Descripteurs français

English descriptors

KwdEn :
- Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Antineoplastic Agents (administration & dosage), Antineoplastic Agents (adverse effects), Antineoplastic Agents (therapeutic use), Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Bridged Bicyclo Compounds, Heterocyclic (administration & dosage), Bridged Bicyclo Compounds, Heterocyclic (adverse effects), Bridged Bicyclo Compounds, Heterocyclic (therapeutic use), Disease Management (MeSH), Drug Resistance, Neoplasm (MeSH), Female (MeSH), Humans (MeSH), Leukemia, Lymphocytic, Chronic, B-Cell (diagnosis), Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy), Leukemia, Lymphocytic, Chronic, B-Cell (genetics), Leukemia, Lymphocytic, Chronic, B-Cell (mortality), Male (MeSH), Middle Aged (MeSH), Recurrence (MeSH), Sulfonamides (administration & dosage), Sulfonamides (adverse effects), Sulfonamides (therapeutic use), Survival Analysis (MeSH), Treatment Outcome (MeSH), Tumor Lysis Syndrome (etiology).
MESH :
- chemical , administration & dosage : Antineoplastic Agents, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides.
- chemical , adverse effects : Antineoplastic Agents, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides.
- chemical , therapeutic use : Antineoplastic Agents, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols.
- diagnosis : Leukemia, Lymphocytic, Chronic, B-Cell.
- drug therapy : Leukemia, Lymphocytic, Chronic, B-Cell.
- etiology : Tumor Lysis Syndrome.
- genetics : Leukemia, Lymphocytic, Chronic, B-Cell.
- mortality : Leukemia, Lymphocytic, Chronic, B-Cell.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adult, Aged, Aged, 80 and over, Disease Management, Drug Resistance, Neoplasm, Female, Humans, Male, Middle Aged, Recurrence, Survival Analysis, Treatment Outcome.

Abstract

Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted a multicenter retrospective cohort analysis of patients with chronic lymphocytic leukemia treated with venetoclax to describe outcomes, toxicities, and treatment selection following venetoclax discontinuation. A total of 141 chronic lymphocytic leukemia patients were included (98% relapsed/refractory). Median age at venetoclax initiation was 67 years (range 37-91), median prior therapies was 3 (0-11), 81% unmutated IGHV, 45% del(17p), and 26.8% complex karyotype (≥ 3 abnormalities). Prior to venetoclax initiation, 89% received a B-cell receptor antagonist. For tumor lysis syndrome prophylaxis, 93% received allopurinol, 92% normal saline, and 45% rasburicase. Dose escalation to the maximum recommended dose of 400 mg daily was achieved in 85% of patients. Adverse events of interest included neutropenia in 47.4%, thrombocytopenia in 36%, tumor lysis syndrome in 13.4%, neutropenic fever in 11.6%, and diarrhea in 7.3%. The overall response rate to venetoclax was 72% (19.4% complete remission). With a median follow up of 7 months, median progression free survival and overall survival for the entire cohort have not been reached. To date, 41 venetoclax treated patients have discontinued therapy and 24 have received a subsequent therapy, most commonly ibrutinib. In the largest clinical experience of venetoclax-treated chronic lymphocytic leukemia patients, the majority successfully completed and maintained a maximum recommended dose. Response rates and duration of response appear comparable to clinical trial data. Venetoclax was active in patients with mutations known to confer ibrutinib resistance. Optimal sequencing of newer chronic lymphocytic leukemia therapies requires further study.

DOI: 10.3324/haematol.2018.193615
PubMed: 29880613
PubMed Central: PMC6119152

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000701
to stream Main, to step Curation: 000701

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.</title>
<author><name sortKey="Mato, Anthony R" sort="Mato, Anthony R" uniqKey="Mato A" first="Anthony R" last="Mato">Anthony R. Mato</name>
<affiliation><nlm:affiliation>CLL Program, Leukemia Service, Division of Hematologic Oncology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA matoa@mskcc.org.</nlm:affiliation>
<wicri:noCountry code="subField">USA matoa@mskcc.org.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Thompson, Meghan" sort="Thompson, Meghan" uniqKey="Thompson M" first="Meghan" last="Thompson">Meghan Thompson</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Allan, John N" sort="Allan, John N" uniqKey="Allan J" first="John N" last="Allan">John N. Allan</name>
<affiliation wicri:level="2"><nlm:affiliation>New York Presbyterian & Weill Cornell, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>New York Presbyterian & Weill Cornell, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brander, Danielle M" sort="Brander, Danielle M" uniqKey="Brander D" first="Danielle M" last="Brander">Danielle M. Brander</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pagel, John M" sort="Pagel, John M" uniqKey="Pagel J" first="John M" last="Pagel">John M. Pagel</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA</wicri:regionArea>
<placeName><region type="state">Washington (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ujjani, Chaitra S" sort="Ujjani, Chaitra S" uniqKey="Ujjani C" first="Chaitra S" last="Ujjani">Chaitra S. Ujjani</name>
<affiliation wicri:level="2"><nlm:affiliation>Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC</wicri:regionArea>
<placeName><region type="state">District de Columbia</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hill, Brian T" sort="Hill, Brian T" uniqKey="Hill B" first="Brian T" last="Hill">Brian T. Hill</name>
<affiliation wicri:level="2"><nlm:affiliation>Taussig Cancer Institute, Cleveland Clinic Foundation, OH, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Taussig Cancer Institute, Cleveland Clinic Foundation, OH</wicri:regionArea>
<placeName><region type="state">Ohio</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lamanna, Nicole" sort="Lamanna, Nicole" uniqKey="Lamanna N" first="Nicole" last="Lamanna">Nicole Lamanna</name>
<affiliation wicri:level="2"><nlm:affiliation>Columbia University Medical Center, New York, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Columbia University Medical Center, New York, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lansigan, Frederick" sort="Lansigan, Frederick" uniqKey="Lansigan F" first="Frederick" last="Lansigan">Frederick Lansigan</name>
<affiliation wicri:level="2"><nlm:affiliation>Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Dartmouth-Hitchcock Medical Center, Lebanon, NH</wicri:regionArea>
<placeName><region type="state">New Hampshire</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jacobs, Ryan" sort="Jacobs, Ryan" uniqKey="Jacobs R" first="Ryan" last="Jacobs">Ryan Jacobs</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shadman, Mazyar" sort="Shadman, Mazyar" uniqKey="Shadman M" first="Mazyar" last="Shadman">Mazyar Shadman</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Washington/Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, WA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Washington/Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, WA</wicri:regionArea>
<placeName><region type="state">Washington (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Skarbnik, Alan P" sort="Skarbnik, Alan P" uniqKey="Skarbnik A" first="Alan P" last="Skarbnik">Alan P. Skarbnik</name>
<affiliation wicri:level="2"><nlm:affiliation>John Theurer Cancer Center, Hackensack Meridian Health, NJ, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>John Theurer Cancer Center, Hackensack Meridian Health, NJ</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pu, Jeffrey J" sort="Pu, Jeffrey J" uniqKey="Pu J" first="Jeffrey J" last="Pu">Jeffrey J. Pu</name>
<affiliation wicri:level="2"><nlm:affiliation>Penn State Health, Hershey, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Penn State Health, Hershey, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Barr, Paul M" sort="Barr, Paul M" uniqKey="Barr P" first="Paul M" last="Barr">Paul M. Barr</name>
<affiliation wicri:level="2"><nlm:affiliation>Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sehgal, Alison R" sort="Sehgal, Alison R" uniqKey="Sehgal A" first="Alison R" last="Sehgal">Alison R. Sehgal</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Pittsburgh Medical Center, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pittsburgh Medical Center, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cheson, Bruce D" sort="Cheson, Bruce D" uniqKey="Cheson B" first="Bruce D" last="Cheson">Bruce D. Cheson</name>
<affiliation wicri:level="2"><nlm:affiliation>Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC</wicri:regionArea>
<placeName><region type="state">District de Columbia</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zent, Clive S" sort="Zent, Clive S" uniqKey="Zent C" first="Clive S" last="Zent">Clive S. Zent</name>
<affiliation wicri:level="2"><nlm:affiliation>Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tuncer, Hande H" sort="Tuncer, Hande H" uniqKey="Tuncer H" first="Hande H" last="Tuncer">Hande H. Tuncer</name>
<affiliation wicri:level="2"><nlm:affiliation>Tufts Medical Center, Boston, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Tufts Medical Center, Boston, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Schuster, Stephen J" sort="Schuster, Stephen J" uniqKey="Schuster S" first="Stephen J" last="Schuster">Stephen J. Schuster</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pickens, Peter V" sort="Pickens, Peter V" uniqKey="Pickens P" first="Peter V" last="Pickens">Peter V. Pickens</name>
<affiliation wicri:level="2"><nlm:affiliation>Abington Hem. Onc. Assoc., Inc., Willow Grove, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Abington Hem. Onc. Assoc., Inc., Willow Grove, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shah, Nirav N" sort="Shah, Nirav N" uniqKey="Shah N" first="Nirav N" last="Shah">Nirav N. Shah</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Hematology & Oncology, Medical College of Wisconsin, Brookfield, WI, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Hematology & Oncology, Medical College of Wisconsin, Brookfield, WI</wicri:regionArea>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Goy, Andre" sort="Goy, Andre" uniqKey="Goy A" first="Andre" last="Goy">Andre Goy</name>
<affiliation wicri:level="2"><nlm:affiliation>John Theurer Cancer Center, Hackensack Meridian Health, NJ, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>John Theurer Cancer Center, Hackensack Meridian Health, NJ</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Winter, Allison M" sort="Winter, Allison M" uniqKey="Winter A" first="Allison M" last="Winter">Allison M. Winter</name>
<affiliation wicri:level="2"><nlm:affiliation>Taussig Cancer Institute, Cleveland Clinic Foundation, OH, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Taussig Cancer Institute, Cleveland Clinic Foundation, OH</wicri:regionArea>
<placeName><region type="state">Ohio</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Garcia, Christine" sort="Garcia, Christine" uniqKey="Garcia C" first="Christine" last="Garcia">Christine Garcia</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Pittsburgh Medical Center, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pittsburgh Medical Center, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kennard, Kaitlin" sort="Kennard, Kaitlin" uniqKey="Kennard K" first="Kaitlin" last="Kennard">Kaitlin Kennard</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Isaac, Krista" sort="Isaac, Krista" uniqKey="Isaac K" first="Krista" last="Isaac">Krista Isaac</name>
<affiliation wicri:level="2"><nlm:affiliation>Internal Medicine, Lankenau Medical Center, Wynnewood, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Internal Medicine, Lankenau Medical Center, Wynnewood, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dorsey, Colleen" sort="Dorsey, Colleen" uniqKey="Dorsey C" first="Colleen" last="Dorsey">Colleen Dorsey</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gashonia, Lisa M" sort="Gashonia, Lisa M" uniqKey="Gashonia L" first="Lisa M" last="Gashonia">Lisa M. Gashonia</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Singavi, Arun K" sort="Singavi, Arun K" uniqKey="Singavi A" first="Arun K" last="Singavi">Arun K. Singavi</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Hematology & Oncology, Medical College of Wisconsin, Brookfield, WI, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Hematology & Oncology, Medical College of Wisconsin, Brookfield, WI</wicri:regionArea>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Roeker, Lindsey E" sort="Roeker, Lindsey E" uniqKey="Roeker L" first="Lindsey E" last="Roeker">Lindsey E. Roeker</name>
<affiliation wicri:level="2"><nlm:affiliation>CLL Program, Leukemia Service, Division of Hematologic Oncology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>CLL Program, Leukemia Service, Division of Hematologic Oncology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zelenetz, Andrew" sort="Zelenetz, Andrew" uniqKey="Zelenetz A" first="Andrew" last="Zelenetz">Andrew Zelenetz</name>
<affiliation wicri:level="2"><nlm:affiliation>CLL Program, Leukemia Service, Division of Hematologic Oncology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>CLL Program, Leukemia Service, Division of Hematologic Oncology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Williams, Annalynn" sort="Williams, Annalynn" uniqKey="Williams A" first="Annalynn" last="Williams">Annalynn Williams</name>
<affiliation wicri:level="2"><nlm:affiliation>Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Howlett, Christina" sort="Howlett, Christina" uniqKey="Howlett C" first="Christina" last="Howlett">Christina Howlett</name>
<affiliation wicri:level="2"><nlm:affiliation>John Theurer Cancer Center, Hackensack Meridian Health, NJ, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>John Theurer Cancer Center, Hackensack Meridian Health, NJ</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Weissbrot, Hanna" sort="Weissbrot, Hanna" uniqKey="Weissbrot H" first="Hanna" last="Weissbrot">Hanna Weissbrot</name>
<affiliation wicri:level="2"><nlm:affiliation>Columbia University Medical Center, New York, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Columbia University Medical Center, New York, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ali, Naveed" sort="Ali, Naveed" uniqKey="Ali N" first="Naveed" last="Ali">Naveed Ali</name>
<affiliation wicri:level="2"><nlm:affiliation>Abington Hem. Onc. Assoc., Inc., Willow Grove, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Abington Hem. Onc. Assoc., Inc., Willow Grove, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Khajavian, Sirin" sort="Khajavian, Sirin" uniqKey="Khajavian S" first="Sirin" last="Khajavian">Sirin Khajavian</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Washington/Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, WA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Washington/Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, WA</wicri:regionArea>
<placeName><region type="state">Washington (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sitlinger, Andrea" sort="Sitlinger, Andrea" uniqKey="Sitlinger A" first="Andrea" last="Sitlinger">Andrea Sitlinger</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tranchito, Eve" sort="Tranchito, Eve" uniqKey="Tranchito E" first="Eve" last="Tranchito">Eve Tranchito</name>
<affiliation wicri:level="2"><nlm:affiliation>Taussig Cancer Institute, Cleveland Clinic Foundation, OH, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Taussig Cancer Institute, Cleveland Clinic Foundation, OH</wicri:regionArea>
<placeName><region type="state">Ohio</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rhodes, Joanna" sort="Rhodes, Joanna" uniqKey="Rhodes J" first="Joanna" last="Rhodes">Joanna Rhodes</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Felsenfeld, Joshua" sort="Felsenfeld, Joshua" uniqKey="Felsenfeld J" first="Joshua" last="Felsenfeld">Joshua Felsenfeld</name>
<affiliation wicri:level="2"><nlm:affiliation>New York Presbyterian & Weill Cornell, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>New York Presbyterian & Weill Cornell, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bailey, Neil" sort="Bailey, Neil" uniqKey="Bailey N" first="Neil" last="Bailey">Neil Bailey</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA</wicri:regionArea>
<placeName><region type="state">Washington (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Patel, Bhavisha" sort="Patel, Bhavisha" uniqKey="Patel B" first="Bhavisha" last="Patel">Bhavisha Patel</name>
<affiliation wicri:level="2"><nlm:affiliation>Washington Hospital Center, DC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Washington Hospital Center, DC</wicri:regionArea>
<placeName><region type="state">District de Columbia</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Burns, Timothy F" sort="Burns, Timothy F" uniqKey="Burns T" first="Timothy F" last="Burns">Timothy F. Burns</name>
<affiliation wicri:level="2"><nlm:affiliation>Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Dartmouth-Hitchcock Medical Center, Lebanon, NH</wicri:regionArea>
<placeName><region type="state">New Hampshire</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yacur, Melissa" sort="Yacur, Melissa" uniqKey="Yacur M" first="Melissa" last="Yacur">Melissa Yacur</name>
<affiliation wicri:level="2"><nlm:affiliation>Penn State Health, Hershey, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Penn State Health, Hershey, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Malhotra, Mansi" sort="Malhotra, Mansi" uniqKey="Malhotra M" first="Mansi" last="Malhotra">Mansi Malhotra</name>
<affiliation wicri:level="2"><nlm:affiliation>Tufts Medical Center, Boston, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Tufts Medical Center, Boston, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Svoboda, Jakub" sort="Svoboda, Jakub" uniqKey="Svoboda J" first="Jakub" last="Svoboda">Jakub Svoboda</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Furman, Richard R" sort="Furman, Richard R" uniqKey="Furman R" first="Richard R" last="Furman">Richard R. Furman</name>
<affiliation wicri:level="2"><nlm:affiliation>New York Presbyterian & Weill Cornell, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>New York Presbyterian & Weill Cornell, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nabhan, Chadi" sort="Nabhan, Chadi" uniqKey="Nabhan C" first="Chadi" last="Nabhan">Chadi Nabhan</name>
<affiliation wicri:level="2"><nlm:affiliation>Cardinal Health, Dublin, OH, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Cardinal Health, Dublin, OH</wicri:regionArea>
<placeName><region type="state">Ohio</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2018">2018</date>
<idno type="RBID">pubmed:29880613</idno>
<idno type="pmid">29880613</idno>
<idno type="doi">10.3324/haematol.2018.193615</idno>
<idno type="pmc">PMC6119152</idno>
<idno type="wicri:Area/Main/Corpus">000701</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000701</idno>
<idno type="wicri:Area/Main/Curation">000701</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000701</idno>
<idno type="wicri:Area/Main/Exploration">000701</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.</title>
<author><name sortKey="Mato, Anthony R" sort="Mato, Anthony R" uniqKey="Mato A" first="Anthony R" last="Mato">Anthony R. Mato</name>
<affiliation><nlm:affiliation>CLL Program, Leukemia Service, Division of Hematologic Oncology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA matoa@mskcc.org.</nlm:affiliation>
<wicri:noCountry code="subField">USA matoa@mskcc.org.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Thompson, Meghan" sort="Thompson, Meghan" uniqKey="Thompson M" first="Meghan" last="Thompson">Meghan Thompson</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Allan, John N" sort="Allan, John N" uniqKey="Allan J" first="John N" last="Allan">John N. Allan</name>
<affiliation wicri:level="2"><nlm:affiliation>New York Presbyterian & Weill Cornell, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>New York Presbyterian & Weill Cornell, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brander, Danielle M" sort="Brander, Danielle M" uniqKey="Brander D" first="Danielle M" last="Brander">Danielle M. Brander</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pagel, John M" sort="Pagel, John M" uniqKey="Pagel J" first="John M" last="Pagel">John M. Pagel</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA</wicri:regionArea>
<placeName><region type="state">Washington (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ujjani, Chaitra S" sort="Ujjani, Chaitra S" uniqKey="Ujjani C" first="Chaitra S" last="Ujjani">Chaitra S. Ujjani</name>
<affiliation wicri:level="2"><nlm:affiliation>Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC</wicri:regionArea>
<placeName><region type="state">District de Columbia</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hill, Brian T" sort="Hill, Brian T" uniqKey="Hill B" first="Brian T" last="Hill">Brian T. Hill</name>
<affiliation wicri:level="2"><nlm:affiliation>Taussig Cancer Institute, Cleveland Clinic Foundation, OH, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Taussig Cancer Institute, Cleveland Clinic Foundation, OH</wicri:regionArea>
<placeName><region type="state">Ohio</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lamanna, Nicole" sort="Lamanna, Nicole" uniqKey="Lamanna N" first="Nicole" last="Lamanna">Nicole Lamanna</name>
<affiliation wicri:level="2"><nlm:affiliation>Columbia University Medical Center, New York, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Columbia University Medical Center, New York, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lansigan, Frederick" sort="Lansigan, Frederick" uniqKey="Lansigan F" first="Frederick" last="Lansigan">Frederick Lansigan</name>
<affiliation wicri:level="2"><nlm:affiliation>Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Dartmouth-Hitchcock Medical Center, Lebanon, NH</wicri:regionArea>
<placeName><region type="state">New Hampshire</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jacobs, Ryan" sort="Jacobs, Ryan" uniqKey="Jacobs R" first="Ryan" last="Jacobs">Ryan Jacobs</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shadman, Mazyar" sort="Shadman, Mazyar" uniqKey="Shadman M" first="Mazyar" last="Shadman">Mazyar Shadman</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Washington/Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, WA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Washington/Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, WA</wicri:regionArea>
<placeName><region type="state">Washington (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Skarbnik, Alan P" sort="Skarbnik, Alan P" uniqKey="Skarbnik A" first="Alan P" last="Skarbnik">Alan P. Skarbnik</name>
<affiliation wicri:level="2"><nlm:affiliation>John Theurer Cancer Center, Hackensack Meridian Health, NJ, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>John Theurer Cancer Center, Hackensack Meridian Health, NJ</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pu, Jeffrey J" sort="Pu, Jeffrey J" uniqKey="Pu J" first="Jeffrey J" last="Pu">Jeffrey J. Pu</name>
<affiliation wicri:level="2"><nlm:affiliation>Penn State Health, Hershey, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Penn State Health, Hershey, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Barr, Paul M" sort="Barr, Paul M" uniqKey="Barr P" first="Paul M" last="Barr">Paul M. Barr</name>
<affiliation wicri:level="2"><nlm:affiliation>Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sehgal, Alison R" sort="Sehgal, Alison R" uniqKey="Sehgal A" first="Alison R" last="Sehgal">Alison R. Sehgal</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Pittsburgh Medical Center, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pittsburgh Medical Center, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cheson, Bruce D" sort="Cheson, Bruce D" uniqKey="Cheson B" first="Bruce D" last="Cheson">Bruce D. Cheson</name>
<affiliation wicri:level="2"><nlm:affiliation>Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC</wicri:regionArea>
<placeName><region type="state">District de Columbia</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zent, Clive S" sort="Zent, Clive S" uniqKey="Zent C" first="Clive S" last="Zent">Clive S. Zent</name>
<affiliation wicri:level="2"><nlm:affiliation>Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tuncer, Hande H" sort="Tuncer, Hande H" uniqKey="Tuncer H" first="Hande H" last="Tuncer">Hande H. Tuncer</name>
<affiliation wicri:level="2"><nlm:affiliation>Tufts Medical Center, Boston, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Tufts Medical Center, Boston, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Schuster, Stephen J" sort="Schuster, Stephen J" uniqKey="Schuster S" first="Stephen J" last="Schuster">Stephen J. Schuster</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pickens, Peter V" sort="Pickens, Peter V" uniqKey="Pickens P" first="Peter V" last="Pickens">Peter V. Pickens</name>
<affiliation wicri:level="2"><nlm:affiliation>Abington Hem. Onc. Assoc., Inc., Willow Grove, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Abington Hem. Onc. Assoc., Inc., Willow Grove, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shah, Nirav N" sort="Shah, Nirav N" uniqKey="Shah N" first="Nirav N" last="Shah">Nirav N. Shah</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Hematology & Oncology, Medical College of Wisconsin, Brookfield, WI, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Hematology & Oncology, Medical College of Wisconsin, Brookfield, WI</wicri:regionArea>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Goy, Andre" sort="Goy, Andre" uniqKey="Goy A" first="Andre" last="Goy">Andre Goy</name>
<affiliation wicri:level="2"><nlm:affiliation>John Theurer Cancer Center, Hackensack Meridian Health, NJ, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>John Theurer Cancer Center, Hackensack Meridian Health, NJ</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Winter, Allison M" sort="Winter, Allison M" uniqKey="Winter A" first="Allison M" last="Winter">Allison M. Winter</name>
<affiliation wicri:level="2"><nlm:affiliation>Taussig Cancer Institute, Cleveland Clinic Foundation, OH, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Taussig Cancer Institute, Cleveland Clinic Foundation, OH</wicri:regionArea>
<placeName><region type="state">Ohio</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Garcia, Christine" sort="Garcia, Christine" uniqKey="Garcia C" first="Christine" last="Garcia">Christine Garcia</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Pittsburgh Medical Center, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pittsburgh Medical Center, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kennard, Kaitlin" sort="Kennard, Kaitlin" uniqKey="Kennard K" first="Kaitlin" last="Kennard">Kaitlin Kennard</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Isaac, Krista" sort="Isaac, Krista" uniqKey="Isaac K" first="Krista" last="Isaac">Krista Isaac</name>
<affiliation wicri:level="2"><nlm:affiliation>Internal Medicine, Lankenau Medical Center, Wynnewood, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Internal Medicine, Lankenau Medical Center, Wynnewood, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dorsey, Colleen" sort="Dorsey, Colleen" uniqKey="Dorsey C" first="Colleen" last="Dorsey">Colleen Dorsey</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gashonia, Lisa M" sort="Gashonia, Lisa M" uniqKey="Gashonia L" first="Lisa M" last="Gashonia">Lisa M. Gashonia</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Singavi, Arun K" sort="Singavi, Arun K" uniqKey="Singavi A" first="Arun K" last="Singavi">Arun K. Singavi</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Hematology & Oncology, Medical College of Wisconsin, Brookfield, WI, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Hematology & Oncology, Medical College of Wisconsin, Brookfield, WI</wicri:regionArea>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Roeker, Lindsey E" sort="Roeker, Lindsey E" uniqKey="Roeker L" first="Lindsey E" last="Roeker">Lindsey E. Roeker</name>
<affiliation wicri:level="2"><nlm:affiliation>CLL Program, Leukemia Service, Division of Hematologic Oncology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>CLL Program, Leukemia Service, Division of Hematologic Oncology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zelenetz, Andrew" sort="Zelenetz, Andrew" uniqKey="Zelenetz A" first="Andrew" last="Zelenetz">Andrew Zelenetz</name>
<affiliation wicri:level="2"><nlm:affiliation>CLL Program, Leukemia Service, Division of Hematologic Oncology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>CLL Program, Leukemia Service, Division of Hematologic Oncology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Williams, Annalynn" sort="Williams, Annalynn" uniqKey="Williams A" first="Annalynn" last="Williams">Annalynn Williams</name>
<affiliation wicri:level="2"><nlm:affiliation>Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Howlett, Christina" sort="Howlett, Christina" uniqKey="Howlett C" first="Christina" last="Howlett">Christina Howlett</name>
<affiliation wicri:level="2"><nlm:affiliation>John Theurer Cancer Center, Hackensack Meridian Health, NJ, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>John Theurer Cancer Center, Hackensack Meridian Health, NJ</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Weissbrot, Hanna" sort="Weissbrot, Hanna" uniqKey="Weissbrot H" first="Hanna" last="Weissbrot">Hanna Weissbrot</name>
<affiliation wicri:level="2"><nlm:affiliation>Columbia University Medical Center, New York, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Columbia University Medical Center, New York, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ali, Naveed" sort="Ali, Naveed" uniqKey="Ali N" first="Naveed" last="Ali">Naveed Ali</name>
<affiliation wicri:level="2"><nlm:affiliation>Abington Hem. Onc. Assoc., Inc., Willow Grove, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Abington Hem. Onc. Assoc., Inc., Willow Grove, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Khajavian, Sirin" sort="Khajavian, Sirin" uniqKey="Khajavian S" first="Sirin" last="Khajavian">Sirin Khajavian</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Washington/Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, WA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Washington/Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, WA</wicri:regionArea>
<placeName><region type="state">Washington (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sitlinger, Andrea" sort="Sitlinger, Andrea" uniqKey="Sitlinger A" first="Andrea" last="Sitlinger">Andrea Sitlinger</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tranchito, Eve" sort="Tranchito, Eve" uniqKey="Tranchito E" first="Eve" last="Tranchito">Eve Tranchito</name>
<affiliation wicri:level="2"><nlm:affiliation>Taussig Cancer Institute, Cleveland Clinic Foundation, OH, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Taussig Cancer Institute, Cleveland Clinic Foundation, OH</wicri:regionArea>
<placeName><region type="state">Ohio</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rhodes, Joanna" sort="Rhodes, Joanna" uniqKey="Rhodes J" first="Joanna" last="Rhodes">Joanna Rhodes</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Felsenfeld, Joshua" sort="Felsenfeld, Joshua" uniqKey="Felsenfeld J" first="Joshua" last="Felsenfeld">Joshua Felsenfeld</name>
<affiliation wicri:level="2"><nlm:affiliation>New York Presbyterian & Weill Cornell, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>New York Presbyterian & Weill Cornell, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bailey, Neil" sort="Bailey, Neil" uniqKey="Bailey N" first="Neil" last="Bailey">Neil Bailey</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA</wicri:regionArea>
<placeName><region type="state">Washington (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Patel, Bhavisha" sort="Patel, Bhavisha" uniqKey="Patel B" first="Bhavisha" last="Patel">Bhavisha Patel</name>
<affiliation wicri:level="2"><nlm:affiliation>Washington Hospital Center, DC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Washington Hospital Center, DC</wicri:regionArea>
<placeName><region type="state">District de Columbia</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Burns, Timothy F" sort="Burns, Timothy F" uniqKey="Burns T" first="Timothy F" last="Burns">Timothy F. Burns</name>
<affiliation wicri:level="2"><nlm:affiliation>Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Dartmouth-Hitchcock Medical Center, Lebanon, NH</wicri:regionArea>
<placeName><region type="state">New Hampshire</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yacur, Melissa" sort="Yacur, Melissa" uniqKey="Yacur M" first="Melissa" last="Yacur">Melissa Yacur</name>
<affiliation wicri:level="2"><nlm:affiliation>Penn State Health, Hershey, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Penn State Health, Hershey, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Malhotra, Mansi" sort="Malhotra, Mansi" uniqKey="Malhotra M" first="Mansi" last="Malhotra">Mansi Malhotra</name>
<affiliation wicri:level="2"><nlm:affiliation>Tufts Medical Center, Boston, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Tufts Medical Center, Boston, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Svoboda, Jakub" sort="Svoboda, Jakub" uniqKey="Svoboda J" first="Jakub" last="Svoboda">Jakub Svoboda</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Furman, Richard R" sort="Furman, Richard R" uniqKey="Furman R" first="Richard R" last="Furman">Richard R. Furman</name>
<affiliation wicri:level="2"><nlm:affiliation>New York Presbyterian & Weill Cornell, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>New York Presbyterian & Weill Cornell, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nabhan, Chadi" sort="Nabhan, Chadi" uniqKey="Nabhan C" first="Chadi" last="Nabhan">Chadi Nabhan</name>
<affiliation wicri:level="2"><nlm:affiliation>Cardinal Health, Dublin, OH, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Cardinal Health, Dublin, OH</wicri:regionArea>
<placeName><region type="state">Ohio</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Haematologica</title>
<idno type="eISSN">1592-8721</idno>
<imprint><date when="2018" type="published">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Aged, 80 and over (MeSH)</term>
<term>Antineoplastic Agents (administration & dosage)</term>
<term>Antineoplastic Agents (adverse effects)</term>
<term>Antineoplastic Agents (therapeutic use)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term>
<term>Bridged Bicyclo Compounds, Heterocyclic (administration & dosage)</term>
<term>Bridged Bicyclo Compounds, Heterocyclic (adverse effects)</term>
<term>Bridged Bicyclo Compounds, Heterocyclic (therapeutic use)</term>
<term>Disease Management (MeSH)</term>
<term>Drug Resistance, Neoplasm (MeSH)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Leukemia, Lymphocytic, Chronic, B-Cell (diagnosis)</term>
<term>Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy)</term>
<term>Leukemia, Lymphocytic, Chronic, B-Cell (genetics)</term>
<term>Leukemia, Lymphocytic, Chronic, B-Cell (mortality)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Recurrence (MeSH)</term>
<term>Sulfonamides (administration & dosage)</term>
<term>Sulfonamides (adverse effects)</term>
<term>Sulfonamides (therapeutic use)</term>
<term>Survival Analysis (MeSH)</term>
<term>Treatment Outcome (MeSH)</term>
<term>Tumor Lysis Syndrome (etiology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Analyse de survie (MeSH)</term>
<term>Antinéoplasiques (administration et posologie)</term>
<term>Antinéoplasiques (effets indésirables)</term>
<term>Antinéoplasiques (usage thérapeutique)</term>
<term>Composés hétérocycliques bicycliques (administration et posologie)</term>
<term>Composés hétérocycliques bicycliques (effets indésirables)</term>
<term>Composés hétérocycliques bicycliques (usage thérapeutique)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Leucémie chronique lymphocytaire à cellules B (diagnostic)</term>
<term>Leucémie chronique lymphocytaire à cellules B (génétique)</term>
<term>Leucémie chronique lymphocytaire à cellules B (mortalité)</term>
<term>Leucémie chronique lymphocytaire à cellules B (traitement médicamenteux)</term>
<term>Mâle (MeSH)</term>
<term>Prise en charge de la maladie (MeSH)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term>
<term>Récidive (MeSH)</term>
<term>Résistance aux médicaments antinéoplasiques (MeSH)</term>
<term>Résultat thérapeutique (MeSH)</term>
<term>Sujet âgé (MeSH)</term>
<term>Sujet âgé de 80 ans ou plus (MeSH)</term>
<term>Sulfonamides (administration et posologie)</term>
<term>Sulfonamides (effets indésirables)</term>
<term>Sulfonamides (usage thérapeutique)</term>
<term>Syndrome de lyse tumorale (étiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Agents</term>
<term>Bridged Bicyclo Compounds, Heterocyclic</term>
<term>Sulfonamides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Agents</term>
<term>Bridged Bicyclo Compounds, Heterocyclic</term>
<term>Sulfonamides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term>
<term>Bridged Bicyclo Compounds, Heterocyclic</term>
<term>Sulfonamides</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antinéoplasiques</term>
<term>Composés hétérocycliques bicycliques</term>
<term>Sulfonamides</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Leukemia, Lymphocytic, Chronic, B-Cell</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Leucémie chronique lymphocytaire à cellules B</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Leukemia, Lymphocytic, Chronic, B-Cell</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antinéoplasiques</term>
<term>Composés hétérocycliques bicycliques</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
<term>Sulfonamides</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Tumor Lysis Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Leukemia, Lymphocytic, Chronic, B-Cell</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Leucémie chronique lymphocytaire à cellules B</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Leukemia, Lymphocytic, Chronic, B-Cell</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Leucémie chronique lymphocytaire à cellules B</term>
</keywords>
<keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Leucémie chronique lymphocytaire à cellules B</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term>
<term>Composés hétérocycliques bicycliques</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
<term>Sulfonamides</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Syndrome de lyse tumorale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Disease Management</term>
<term>Drug Resistance, Neoplasm</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Recurrence</term>
<term>Survival Analysis</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Analyse de survie</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Prise en charge de la maladie</term>
<term>Récidive</term>
<term>Résistance aux médicaments antinéoplasiques</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted a multicenter retrospective cohort analysis of patients with chronic lymphocytic leukemia treated with venetoclax to describe outcomes, toxicities, and treatment selection following venetoclax discontinuation. A total of 141 chronic lymphocytic leukemia patients were included (98% relapsed/refractory). Median age at venetoclax initiation was 67 years (range 37-91), median prior therapies was 3 (0-11), 81% unmutated <i>IGHV</i>
, 45% del(17p), and 26.8% complex karyotype (≥ 3 abnormalities). Prior to venetoclax initiation, 89% received a B-cell receptor antagonist. For tumor lysis syndrome prophylaxis, 93% received allopurinol, 92% normal saline, and 45% rasburicase. Dose escalation to the maximum recommended dose of 400 mg daily was achieved in 85% of patients. Adverse events of interest included neutropenia in 47.4%, thrombocytopenia in 36%, tumor lysis syndrome in 13.4%, neutropenic fever in 11.6%, and diarrhea in 7.3%. The overall response rate to venetoclax was 72% (19.4% complete remission). With a median follow up of 7 months, median progression free survival and overall survival for the entire cohort have not been reached. To date, 41 venetoclax treated patients have discontinued therapy and 24 have received a subsequent therapy, most commonly ibrutinib. In the largest clinical experience of venetoclax-treated chronic lymphocytic leukemia patients, the majority successfully completed and maintained a maximum recommended dose. Response rates and duration of response appear comparable to clinical trial data. Venetoclax was active in patients with mutations known to confer ibrutinib resistance. Optimal sequencing of newer chronic lymphocytic leukemia therapies requires further study.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29880613</PMID>
<DateCompleted><Year>2019</Year>
<Month>09</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>08</Month>
<Day>27</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1592-8721</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>103</Volume>
<Issue>9</Issue>
<PubDate><Year>2018</Year>
<Month>09</Month>
</PubDate>
</JournalIssue>
<Title>Haematologica</Title>
<ISOAbbreviation>Haematologica</ISOAbbreviation>
</Journal>
<ArticleTitle>Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.</ArticleTitle>
<Pagination><MedlinePgn>1511-1517</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3324/haematol.2018.193615</ELocationID>
<Abstract><AbstractText>Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted a multicenter retrospective cohort analysis of patients with chronic lymphocytic leukemia treated with venetoclax to describe outcomes, toxicities, and treatment selection following venetoclax discontinuation. A total of 141 chronic lymphocytic leukemia patients were included (98% relapsed/refractory). Median age at venetoclax initiation was 67 years (range 37-91), median prior therapies was 3 (0-11), 81% unmutated <i>IGHV</i>
, 45% del(17p), and 26.8% complex karyotype (≥ 3 abnormalities). Prior to venetoclax initiation, 89% received a B-cell receptor antagonist. For tumor lysis syndrome prophylaxis, 93% received allopurinol, 92% normal saline, and 45% rasburicase. Dose escalation to the maximum recommended dose of 400 mg daily was achieved in 85% of patients. Adverse events of interest included neutropenia in 47.4%, thrombocytopenia in 36%, tumor lysis syndrome in 13.4%, neutropenic fever in 11.6%, and diarrhea in 7.3%. The overall response rate to venetoclax was 72% (19.4% complete remission). With a median follow up of 7 months, median progression free survival and overall survival for the entire cohort have not been reached. To date, 41 venetoclax treated patients have discontinued therapy and 24 have received a subsequent therapy, most commonly ibrutinib. In the largest clinical experience of venetoclax-treated chronic lymphocytic leukemia patients, the majority successfully completed and maintained a maximum recommended dose. Response rates and duration of response appear comparable to clinical trial data. Venetoclax was active in patients with mutations known to confer ibrutinib resistance. Optimal sequencing of newer chronic lymphocytic leukemia therapies requires further study.</AbstractText>
<CopyrightInformation>Copyright© 2018 Ferrata Storti Foundation.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mato</LastName>
<ForeName>Anthony R</ForeName>
<Initials>AR</Initials>
<AffiliationInfo><Affiliation>CLL Program, Leukemia Service, Division of Hematologic Oncology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA matoa@mskcc.org.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Thompson</LastName>
<ForeName>Meghan</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Allan</LastName>
<ForeName>John N</ForeName>
<Initials>JN</Initials>
<AffiliationInfo><Affiliation>New York Presbyterian & Weill Cornell, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Brander</LastName>
<ForeName>Danielle M</ForeName>
<Initials>DM</Initials>
<AffiliationInfo><Affiliation>Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pagel</LastName>
<ForeName>John M</ForeName>
<Initials>JM</Initials>
<AffiliationInfo><Affiliation>Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ujjani</LastName>
<ForeName>Chaitra S</ForeName>
<Initials>CS</Initials>
<AffiliationInfo><Affiliation>Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hill</LastName>
<ForeName>Brian T</ForeName>
<Initials>BT</Initials>
<AffiliationInfo><Affiliation>Taussig Cancer Institute, Cleveland Clinic Foundation, OH, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lamanna</LastName>
<ForeName>Nicole</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Columbia University Medical Center, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lansigan</LastName>
<ForeName>Frederick</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jacobs</LastName>
<ForeName>Ryan</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shadman</LastName>
<ForeName>Mazyar</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>University of Washington/Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, WA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Skarbnik</LastName>
<ForeName>Alan P</ForeName>
<Initials>AP</Initials>
<AffiliationInfo><Affiliation>John Theurer Cancer Center, Hackensack Meridian Health, NJ, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pu</LastName>
<ForeName>Jeffrey J</ForeName>
<Initials>JJ</Initials>
<AffiliationInfo><Affiliation>Penn State Health, Hershey, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Barr</LastName>
<ForeName>Paul M</ForeName>
<Initials>PM</Initials>
<AffiliationInfo><Affiliation>Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sehgal</LastName>
<ForeName>Alison R</ForeName>
<Initials>AR</Initials>
<AffiliationInfo><Affiliation>University of Pittsburgh Medical Center, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cheson</LastName>
<ForeName>Bruce D</ForeName>
<Initials>BD</Initials>
<AffiliationInfo><Affiliation>Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zent</LastName>
<ForeName>Clive S</ForeName>
<Initials>CS</Initials>
<AffiliationInfo><Affiliation>Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tuncer</LastName>
<ForeName>Hande H</ForeName>
<Initials>HH</Initials>
<AffiliationInfo><Affiliation>Tufts Medical Center, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Schuster</LastName>
<ForeName>Stephen J</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo><Affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pickens</LastName>
<ForeName>Peter V</ForeName>
<Initials>PV</Initials>
<AffiliationInfo><Affiliation>Abington Hem. Onc. Assoc., Inc., Willow Grove, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shah</LastName>
<ForeName>Nirav N</ForeName>
<Initials>NN</Initials>
<AffiliationInfo><Affiliation>Division of Hematology & Oncology, Medical College of Wisconsin, Brookfield, WI, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Goy</LastName>
<ForeName>Andre</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>John Theurer Cancer Center, Hackensack Meridian Health, NJ, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Winter</LastName>
<ForeName>Allison M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo><Affiliation>Taussig Cancer Institute, Cleveland Clinic Foundation, OH, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Garcia</LastName>
<ForeName>Christine</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>University of Pittsburgh Medical Center, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kennard</LastName>
<ForeName>Kaitlin</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Isaac</LastName>
<ForeName>Krista</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Internal Medicine, Lankenau Medical Center, Wynnewood, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dorsey</LastName>
<ForeName>Colleen</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gashonia</LastName>
<ForeName>Lisa M</ForeName>
<Initials>LM</Initials>
<AffiliationInfo><Affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Singavi</LastName>
<ForeName>Arun K</ForeName>
<Initials>AK</Initials>
<AffiliationInfo><Affiliation>Division of Hematology & Oncology, Medical College of Wisconsin, Brookfield, WI, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Roeker</LastName>
<ForeName>Lindsey E</ForeName>
<Initials>LE</Initials>
<AffiliationInfo><Affiliation>CLL Program, Leukemia Service, Division of Hematologic Oncology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zelenetz</LastName>
<ForeName>Andrew</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>CLL Program, Leukemia Service, Division of Hematologic Oncology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Williams</LastName>
<ForeName>Annalynn</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Howlett</LastName>
<ForeName>Christina</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>John Theurer Cancer Center, Hackensack Meridian Health, NJ, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Weissbrot</LastName>
<ForeName>Hanna</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Columbia University Medical Center, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ali</LastName>
<ForeName>Naveed</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Abington Hem. Onc. Assoc., Inc., Willow Grove, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Khajavian</LastName>
<ForeName>Sirin</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>University of Washington/Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, WA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sitlinger</LastName>
<ForeName>Andrea</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tranchito</LastName>
<ForeName>Eve</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Taussig Cancer Institute, Cleveland Clinic Foundation, OH, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rhodes</LastName>
<ForeName>Joanna</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Felsenfeld</LastName>
<ForeName>Joshua</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>New York Presbyterian & Weill Cornell, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bailey</LastName>
<ForeName>Neil</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Patel</LastName>
<ForeName>Bhavisha</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Washington Hospital Center, DC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Burns</LastName>
<ForeName>Timothy F</ForeName>
<Initials>TF</Initials>
<AffiliationInfo><Affiliation>Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yacur</LastName>
<ForeName>Melissa</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Penn State Health, Hershey, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Malhotra</LastName>
<ForeName>Mansi</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Tufts Medical Center, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Svoboda</LastName>
<ForeName>Jakub</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Center for CLL, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Furman</LastName>
<ForeName>Richard R</ForeName>
<Initials>RR</Initials>
<AffiliationInfo><Affiliation>New York Presbyterian & Weill Cornell, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nabhan</LastName>
<ForeName>Chadi</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Cardinal Health, Dublin, OH, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>P30 CA008748</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>T32 HL007057</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2018</Year>
<Month>06</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Italy</Country>
<MedlineTA>Haematologica</MedlineTA>
<NlmUniqueID>0417435</NlmUniqueID>
<ISSNLinking>0390-6078</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019086">Bridged Bicyclo Compounds, Heterocyclic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>N54AIC43PW</RegistryNumber>
<NameOfSubstance UI="C579720">venetoclax</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019086" MajorTopicYN="N">Bridged Bicyclo Compounds, Heterocyclic</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019468" MajorTopicYN="N">Disease Management</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015451" MajorTopicYN="N">Leukemia, Lymphocytic, Chronic, B-Cell</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015275" MajorTopicYN="N">Tumor Lysis Syndrome</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year>
<Month>03</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2018</Year>
<Month>06</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2018</Year>
<Month>6</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>9</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2018</Year>
<Month>6</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">29880613</ArticleId>
<ArticleId IdType="pii">haematol.2018.193615</ArticleId>
<ArticleId IdType="doi">10.3324/haematol.2018.193615</ArticleId>
<ArticleId IdType="pmc">PMC6119152</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>N Engl J Med. 2016 Jan 28;374(4):311-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26639348</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Oncol. 2017 May 1;28(5):1050-1056</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28453705</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Haematologica. 2016 Dec;101(12):1563-1572</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27756834</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Oncol. 2018 Jan;19(1):65-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29246803</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2008 Jun 15;111(12):5446-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18216293</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Oncol. 2016 Jun;17(6):768-778</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27178240</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Haematologica. 2018 May;103(5):874-879</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29419429</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 1998 Dec 5;317(7172):1572</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9836663</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2011 May 12;364(19):1844-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21561350</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2018 Mar 22;378(12):1107-1120</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29562156</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2017 Jun 22;129(25):3362-3370</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28473407</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2016 Nov 3;128(18):2199-2205</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27601462</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2018 Apr 12;131(15):1704-1711</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29305552</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Caroline du Nord</li>
<li>District de Columbia</li>
<li>Massachusetts</li>
<li>New Hampshire</li>
<li>New Jersey</li>
<li>Ohio</li>
<li>Pennsylvanie</li>
<li>Washington (État)</li>
<li>Wisconsin</li>
<li>État de New York</li>
</region>
</list>
<tree><noCountry><name sortKey="Mato, Anthony R" sort="Mato, Anthony R" uniqKey="Mato A" first="Anthony R" last="Mato">Anthony R. Mato</name>
</noCountry>
<country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Thompson, Meghan" sort="Thompson, Meghan" uniqKey="Thompson M" first="Meghan" last="Thompson">Meghan Thompson</name>
</region>
<name sortKey="Ali, Naveed" sort="Ali, Naveed" uniqKey="Ali N" first="Naveed" last="Ali">Naveed Ali</name>
<name sortKey="Allan, John N" sort="Allan, John N" uniqKey="Allan J" first="John N" last="Allan">John N. Allan</name>
<name sortKey="Bailey, Neil" sort="Bailey, Neil" uniqKey="Bailey N" first="Neil" last="Bailey">Neil Bailey</name>
<name sortKey="Barr, Paul M" sort="Barr, Paul M" uniqKey="Barr P" first="Paul M" last="Barr">Paul M. Barr</name>
<name sortKey="Brander, Danielle M" sort="Brander, Danielle M" uniqKey="Brander D" first="Danielle M" last="Brander">Danielle M. Brander</name>
<name sortKey="Burns, Timothy F" sort="Burns, Timothy F" uniqKey="Burns T" first="Timothy F" last="Burns">Timothy F. Burns</name>
<name sortKey="Cheson, Bruce D" sort="Cheson, Bruce D" uniqKey="Cheson B" first="Bruce D" last="Cheson">Bruce D. Cheson</name>
<name sortKey="Dorsey, Colleen" sort="Dorsey, Colleen" uniqKey="Dorsey C" first="Colleen" last="Dorsey">Colleen Dorsey</name>
<name sortKey="Felsenfeld, Joshua" sort="Felsenfeld, Joshua" uniqKey="Felsenfeld J" first="Joshua" last="Felsenfeld">Joshua Felsenfeld</name>
<name sortKey="Furman, Richard R" sort="Furman, Richard R" uniqKey="Furman R" first="Richard R" last="Furman">Richard R. Furman</name>
<name sortKey="Garcia, Christine" sort="Garcia, Christine" uniqKey="Garcia C" first="Christine" last="Garcia">Christine Garcia</name>
<name sortKey="Gashonia, Lisa M" sort="Gashonia, Lisa M" uniqKey="Gashonia L" first="Lisa M" last="Gashonia">Lisa M. Gashonia</name>
<name sortKey="Goy, Andre" sort="Goy, Andre" uniqKey="Goy A" first="Andre" last="Goy">Andre Goy</name>
<name sortKey="Hill, Brian T" sort="Hill, Brian T" uniqKey="Hill B" first="Brian T" last="Hill">Brian T. Hill</name>
<name sortKey="Howlett, Christina" sort="Howlett, Christina" uniqKey="Howlett C" first="Christina" last="Howlett">Christina Howlett</name>
<name sortKey="Isaac, Krista" sort="Isaac, Krista" uniqKey="Isaac K" first="Krista" last="Isaac">Krista Isaac</name>
<name sortKey="Jacobs, Ryan" sort="Jacobs, Ryan" uniqKey="Jacobs R" first="Ryan" last="Jacobs">Ryan Jacobs</name>
<name sortKey="Kennard, Kaitlin" sort="Kennard, Kaitlin" uniqKey="Kennard K" first="Kaitlin" last="Kennard">Kaitlin Kennard</name>
<name sortKey="Khajavian, Sirin" sort="Khajavian, Sirin" uniqKey="Khajavian S" first="Sirin" last="Khajavian">Sirin Khajavian</name>
<name sortKey="Lamanna, Nicole" sort="Lamanna, Nicole" uniqKey="Lamanna N" first="Nicole" last="Lamanna">Nicole Lamanna</name>
<name sortKey="Lansigan, Frederick" sort="Lansigan, Frederick" uniqKey="Lansigan F" first="Frederick" last="Lansigan">Frederick Lansigan</name>
<name sortKey="Malhotra, Mansi" sort="Malhotra, Mansi" uniqKey="Malhotra M" first="Mansi" last="Malhotra">Mansi Malhotra</name>
<name sortKey="Nabhan, Chadi" sort="Nabhan, Chadi" uniqKey="Nabhan C" first="Chadi" last="Nabhan">Chadi Nabhan</name>
<name sortKey="Pagel, John M" sort="Pagel, John M" uniqKey="Pagel J" first="John M" last="Pagel">John M. Pagel</name>
<name sortKey="Patel, Bhavisha" sort="Patel, Bhavisha" uniqKey="Patel B" first="Bhavisha" last="Patel">Bhavisha Patel</name>
<name sortKey="Pickens, Peter V" sort="Pickens, Peter V" uniqKey="Pickens P" first="Peter V" last="Pickens">Peter V. Pickens</name>
<name sortKey="Pu, Jeffrey J" sort="Pu, Jeffrey J" uniqKey="Pu J" first="Jeffrey J" last="Pu">Jeffrey J. Pu</name>
<name sortKey="Rhodes, Joanna" sort="Rhodes, Joanna" uniqKey="Rhodes J" first="Joanna" last="Rhodes">Joanna Rhodes</name>
<name sortKey="Roeker, Lindsey E" sort="Roeker, Lindsey E" uniqKey="Roeker L" first="Lindsey E" last="Roeker">Lindsey E. Roeker</name>
<name sortKey="Schuster, Stephen J" sort="Schuster, Stephen J" uniqKey="Schuster S" first="Stephen J" last="Schuster">Stephen J. Schuster</name>
<name sortKey="Sehgal, Alison R" sort="Sehgal, Alison R" uniqKey="Sehgal A" first="Alison R" last="Sehgal">Alison R. Sehgal</name>
<name sortKey="Shadman, Mazyar" sort="Shadman, Mazyar" uniqKey="Shadman M" first="Mazyar" last="Shadman">Mazyar Shadman</name>
<name sortKey="Shah, Nirav N" sort="Shah, Nirav N" uniqKey="Shah N" first="Nirav N" last="Shah">Nirav N. Shah</name>
<name sortKey="Singavi, Arun K" sort="Singavi, Arun K" uniqKey="Singavi A" first="Arun K" last="Singavi">Arun K. Singavi</name>
<name sortKey="Sitlinger, Andrea" sort="Sitlinger, Andrea" uniqKey="Sitlinger A" first="Andrea" last="Sitlinger">Andrea Sitlinger</name>
<name sortKey="Skarbnik, Alan P" sort="Skarbnik, Alan P" uniqKey="Skarbnik A" first="Alan P" last="Skarbnik">Alan P. Skarbnik</name>
<name sortKey="Svoboda, Jakub" sort="Svoboda, Jakub" uniqKey="Svoboda J" first="Jakub" last="Svoboda">Jakub Svoboda</name>
<name sortKey="Tranchito, Eve" sort="Tranchito, Eve" uniqKey="Tranchito E" first="Eve" last="Tranchito">Eve Tranchito</name>
<name sortKey="Tuncer, Hande H" sort="Tuncer, Hande H" uniqKey="Tuncer H" first="Hande H" last="Tuncer">Hande H. Tuncer</name>
<name sortKey="Ujjani, Chaitra S" sort="Ujjani, Chaitra S" uniqKey="Ujjani C" first="Chaitra S" last="Ujjani">Chaitra S. Ujjani</name>
<name sortKey="Weissbrot, Hanna" sort="Weissbrot, Hanna" uniqKey="Weissbrot H" first="Hanna" last="Weissbrot">Hanna Weissbrot</name>
<name sortKey="Williams, Annalynn" sort="Williams, Annalynn" uniqKey="Williams A" first="Annalynn" last="Williams">Annalynn Williams</name>
<name sortKey="Winter, Allison M" sort="Winter, Allison M" uniqKey="Winter A" first="Allison M" last="Winter">Allison M. Winter</name>
<name sortKey="Yacur, Melissa" sort="Yacur, Melissa" uniqKey="Yacur M" first="Melissa" last="Yacur">Melissa Yacur</name>
<name sortKey="Zelenetz, Andrew" sort="Zelenetz, Andrew" uniqKey="Zelenetz A" first="Andrew" last="Zelenetz">Andrew Zelenetz</name>
<name sortKey="Zent, Clive S" sort="Zent, Clive S" uniqKey="Zent C" first="Clive S" last="Zent">Clive S. Zent</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/WillowV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000666 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000666 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    WillowV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:29880613
   |texte=   Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:29880613" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a WillowV1

This area was generated with Dilib version V0.6.37.
Data generation: Tue Nov 17 16:35:40 2020. Site generation: Tue Nov 17 16:39:32 2020

	Serveur d'exploration sur le saule
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le saule

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki